Sermorelin vs Ipamorelin vs Tesamorelin: What the Research Literature Compares
Last reviewed: September 2026
Search “ipamorelin vs sermorelin” or “tesamorelin vs CJC-1295” and every result is a clinic telling you which one is right for you. This page is the other kind of comparison. Sermorelin, tesamorelin, CJC-1295 and ipamorelin are four research peptides that act on the same physiological axis — the one that controls growth-hormone release from the pituitary — through two different mechanisms, and the interesting differences between them are pharmacological: which receptor each binds, how long each persists, how selective each is, and how deep the published evidence runs. Those are the comparisons below. Quantum stocks two of the four as research materials, does not stock sermorelin, and says so.
Two mechanisms, one axis: GHRH analogues vs ghrelin-receptor agonists
Growth-hormone release from the anterior pituitary is governed by two stimulatory inputs. Growth-hormone-releasing hormone (GHRH), a 44-amino-acid hypothalamic peptide, acts on the GHRH receptor on pituitary somatotroph cells. Ghrelin, a stomach-derived peptide, acts on a separate receptor — the growth-hormone secretagogue receptor, GHS-R1a — on the same cells and in the hypothalamus. The two signals are synergistic in the models that have tested them together. Every compound on this page is an analogue of one input or the other, which is the single most useful fact for reading any comparison:
| Compound | Class | Receptor | Structure / modification | Half-life class (literature) | Regulatory status |
|---|---|---|---|---|---|
| Sermorelin | GHRH analogue | GHRH receptor | GHRH(1–29), the minimal active fragment of native GHRH; unmodified | Minutes | Former pharmaceutical (US, withdrawn 2008); no authorized product in Canada; not stocked by Quantum |
| Tesamorelin | GHRH analogue | GHRH receptor | GHRH(1–44) with an N-terminal trans-3-hexenoyl group that resists enzymatic cleavage | Tens of minutes | API of Egrifta, a US-approved prescription drug for a specific HIV-associated indication; research material not authorized in Canada |
| CJC-1295 | GHRH analogue | GHRH receptor | GHRH(1–29) with four amino-acid substitutions; the DAC form adds an albumin-binding linker | Days (DAC form); ~30 min (no-DAC “modified GRF 1–29”) | Never an approved pharmaceutical; not authorized in Canada |
| Ipamorelin | Growth-hormone secretagogue (ghrelin mimetic) | GHS-R1a | Synthetic pentapeptide | Around two hours | Never an approved pharmaceutical; not authorized in Canada |
Three of the four are GHRH-side compounds distinguished mainly by how they have been stabilised; ipamorelin is the odd one out, working through the ghrelin receptor. That is why ipamorelin is so often studied alongside a GHRH analogue rather than instead of one.
Ipamorelin vs sermorelin
Sermorelin vs ipamorelin is the most-searched pairing here, and it is a comparison across the two mechanisms rather than within one.
Receptor and selectivity findings
Sermorelin is the first 29 amino acids of human GHRH — the shortest fragment that retains full activity at the GHRH receptor — synthesised without further modification. In the pituitary-cell and animal literature it does what native GHRH does: it stimulates growth-hormone release in a pulsatile pattern that follows the physiological rhythm, and it is cleared within minutes by the same peptidases that clear GHRH. Its research history is the oldest of the four; it was developed in the 1980s and used for years as a diagnostic and therapeutic pharmaceutical before withdrawal. Ipamorelin is a synthetic pentapeptide from the ghrelin-mimetic class, and the finding that defines it in the literature is selectivity: in the 1998 characterisation studies in rats and pigs, ipamorelin stimulated growth-hormone release without the accompanying rise in cortisol, ACTH or prolactin that earlier secretagogues in its class produced. That selectivity finding is a property of the compound in those animal models, and it is the reason ipamorelin, rather than an older secretagogue, is the one that appears in modern GH-axis research.
Why they appear together in research
Because the two receptors are synergistic. Co-administration studies of a GHRH analogue with a GHS-R1a agonist report a greater growth-hormone response in the model than either alone, which is the physiological rationale for the paired-compound designs that dominate the research literature — a GHRH-side compound to drive the pulse and a ghrelin-side compound to amplify it. Research-grade versions of that pairing are available in Canada as CJC-1295 + ipamorelin and tesamorelin + ipamorelin, each with a per-batch Certificate of Analysis, for laboratory research only.
Tesamorelin vs ipamorelin and vs sermorelin
Tesamorelin is the compound on this page with the deepest human evidence base, for a reason that has nothing to do with research-peptide marketing: it is the active ingredient of Egrifta, a prescription drug approved by the US FDA in 2010 for a specific indication in HIV patients, developed by a Montréal-based pharmaceutical company, and it went through the full clinical-trial programme that approval requires. That is a regulatory fact about a drug product, stated here as context; research-grade tesamorelin is not that product and is not supplied as a substitute for it. Structurally, tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoyl group attached at the N-terminus, which protects it from the enzyme that cleaves native GHRH and sermorelin within minutes; the result in the literature is a longer-acting GHRH analogue whose downstream effects on the GH–IGF-1 axis were characterised in controlled human trials. Against sermorelin, then, the comparison is between the same receptor reached by an unmodified fragment with minutes of activity and an older, thinner literature, and a stabilised full-length analogue with a large, modern clinical record. Against ipamorelin, it is a comparison across mechanisms: tesamorelin drives the GHRH receptor and carries human trial data; ipamorelin acts at the ghrelin receptor and its record is largely preclinical, with selectivity as its distinguishing finding. That evidence gradient — tesamorelin deepest, sermorelin older and shallower, ipamorelin mostly animal — is the honest ranking, and no clinic page publishes it.
Tesamorelin vs CJC-1295
Both are GHRH analogues acting at the same receptor, so the research difference is pharmacokinetic. CJC-1295 starts from the GHRH(1–29) fragment and introduces four amino-acid substitutions that resist enzymatic degradation; in its DAC form it also carries a drug-affinity-complex linker that binds serum albumin, and the published pharmacokinetic work reports a half-life measured in days rather than minutes and sustained rather than pulsatile elevation of GH and IGF-1 in the models studied. The no-DAC variant, often called modified GRF(1–29), keeps the substitutions but not the linker and behaves more like a short-acting analogue. Tesamorelin’s stabilisation is a single N-terminal modification on the full 44-residue sequence, giving a shorter extension of activity than DAC-linked CJC-1295 and a pulsatile profile closer to native GHRH. Which pharmacokinetic profile is preferable depends entirely on the research question. The research materials are on the tesamorelin + ipamorelin and CJC-1295 + ipamorelin product pages, which carry the compound-specific detail.
Sermorelin availability in Canada
Quantum does not stock sermorelin. Its pharmaceutical form was withdrawn from the North American market in 2008 for commercial reasons, no sermorelin drug product is authorized for sale in Canada, and research-grade sermorelin from any supplier is a laboratory material that is not for human use. Researchers comparing GHRH analogues typically source the stabilised compounds instead — tesamorelin or CJC-1295 — usually in the blended formats above that pair them with ipamorelin, since the paired design is what most of the modern literature uses. If sermorelin is ever added to the catalogue this page will say so; until then, a search for “sermorelin Canada” that lands here has found the honest answer rather than a product page.
How GH-secretagogue studies are actually run
The foundational assay is in vitro: dispersed rat pituitary cells in culture are exposed to the compound, and growth hormone released into the medium is measured by immunoassay, which is how receptor activity, potency and synergy between GHRH-side and ghrelin-side compounds are established. Animal studies add pharmacokinetics and pulsatility — serial blood sampling in rats, pigs or dogs after administration by a defined route, with GH measured at intervals to build a release curve, and IGF-1 measured over days as the downstream axis readout. Selectivity is assessed by measuring cortisol, ACTH and prolactin in the same samples, which is the design that produced ipamorelin’s defining finding. Human data exist only where a compound went through a pharmaceutical programme, which on this page means tesamorelin and, historically, sermorelin. Every finding above comes from one of these designs and answers a question about that model.
Regulatory status in Canada
None of the four compounds is authorized by Health Canada for human use in the form in which research suppliers sell it. Sermorelin has no authorized product in Canada; CJC-1295 and ipamorelin have never been approved pharmaceuticals anywhere; tesamorelin’s approved form is a specific prescription drug product, and research-grade tesamorelin is not that product. Health Canada’s April 2026 public advisory on unauthorised peptides sold online states that peptides are generally regulated as prescription drugs in Canada and that unauthorised products have not been assessed for safety, efficacy or quality; research-labelled peptides are laboratory materials supplied on that basis, for in-vitro research only. The framework is explained in plain language on are peptides legal in Canada? Where these compounds also appear in sleep research — through the coupling between GHRH activity and slow-wave sleep — is covered in the sleep peptides guide.
Sourcing GH-secretagogue research peptides in Canada
The checks are the standard ones: a per-batch Certificate of Analysis from a named independent laboratory reporting HPLC purity and mass-spectrometry identity — which matters doubly for blends, where the certificate should identify both peptides — a batch number on the vial that matches the published report, cold and dark handling, and a supplier that keeps its product pages inside the research framework. Quantum’s batches are tested by Peptide Test Canada with the reports on the Certificate of Analysis hub; the sourcing process is walked through in how to buy research peptides in Canada, and the catalogue is in the shop.
Frequently asked questions
What is the difference between sermorelin and ipamorelin?
They belong to different classes. Sermorelin is a GHRH(1–29) analogue that acts on the GHRH receptor; ipamorelin is a synthetic pentapeptide that acts on the ghrelin receptor, GHS-R1a, and is noted in animal studies for stimulating growth-hormone release without raising cortisol or prolactin. They are compared in laboratory GH-axis research as complementary compounds, not interchangeable ones.
Do I need a prescription for sermorelin?
The question presumes a drug that no longer exists in this market. Sermorelin’s pharmaceutical form was withdrawn from North America in 2008, no sermorelin drug product is authorized for sale in Canada, and research-labelled sermorelin is a laboratory material that is not for human use. Quantum does not stock it.
Is sermorelin a synthetic peptide?
Yes. Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth-hormone-releasing hormone — the shortest fragment with full activity at the GHRH receptor. It was developed in the 1980s and was used as a pharmaceutical before its withdrawal.
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogues acting at the same receptor, but tesamorelin is the full 44-residue sequence stabilised by an N-terminal trans-3-hexenoyl group, while CJC-1295 is a substituted GHRH(1–29) fragment, with or without an albumin-binding linker that extends its half-life to days. Tesamorelin is the active ingredient of a US-approved prescription drug; CJC-1295 has never been an approved pharmaceutical.
Which GH secretagogue is most studied?
Tesamorelin, by a wide margin, because it went through a full pharmaceutical clinical-trial programme; sermorelin has an older and thinner human record from its years as a drug; CJC-1295’s literature is mainly pharmacokinetic; and ipamorelin’s record is largely preclinical. “Most studied” is the only ranking the evidence supports — it says nothing about which is “best,” a question that presumes a use these research materials are not supplied for.
All compounds referenced on this page are supplied for laboratory research use only and are not for human or veterinary use. Literature statements summarise published in-vitro, animal and clinical-trial findings and are not claims about any product. Egrifta and FDA references are regulatory facts about a separate drug product. Page last reviewed September 2026.